Neumora Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Neumora Therapeutics

04/08/2025 22:14

Neumora Therapeutics Inc NMRA.OQ NMRA.O is expected to  show no change in quarterly revenue when it reports  results on August 6 for the period ending June 30 2025

​LSEG's mean analyst estimate for Neumora Therapeutics Inc is for a loss of 37 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Neumora Therapeutics Inc is $5.00, about 68.8% above its last closing price of $1.56

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.35
-0.37
-0.42
Missed
-12.2
Dec. 31 2025
-0.46
-0.45
-0.37
Beat
17.1
Sep. 30 2024
-0.38
-0.39
-0.45
Missed
-15.4​
Jun. 30 2024
-0.38
-0.37
-0.37
Met
0.4
​​Mar. 31 2024
-0.34
-0.34
-0.34
Met
0.6
Dec. 31 2023
-0.73
-0.55
-0.71
Missed
-29.1​
Sep. 30 2023
-0.36
-0.36
-1.14
Missed
-214.5

This summary was machine generated August 4 at 21:14 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)